Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agree. Look at that volume to price ratio, per chart, and it is clearly evident someone is attempting to manipulate the pps just being malicious or foolish at this point in time, aren't they?
Money Flow(MFI-CMF) and Accumulation(Accum/Dist) indicators are still going steady and strong for SNDZ, no selling shows most believe in the potential of more to come here, doesn't it?
Sunridge International to Present at FSX Conference in San Francisco, CA
On Monday April 12, 2010, 9:00 am EDT
FOUNTAIN HILLS, Ariz., April 12 /PRNewswire-FirstCall/ -- Sunridge International, (OTC Bulletin Board:SNDZ.ob - News) will be presenting at the upcoming FSX (Financial Services Exchange, Inc.) investors conference being held in San Francisco, CA on April 29-May 1, 2010.
Sunridge International's CEO, G. Richard Smith, said, "Our marketing outreach program over the past two months has been a great success in gaining awareness throughout the U.S. investment community. This upcoming FSX Conference will allow us to continue to further our efforts to communicate the progress that Sunridge has made in recent months and the inroads it has made in several of the world's major markets."
About FSX
FSX hosts quarterly investment conferences around the country, providing opportunities for networking and one-on-one communication between independent broker/dealers and companies seeking exposure or funding. FSX is the oldest, most established U.S. forum for independent broker/dealers, and has raised over $1.5 billion for its presenters in the past 24 years. FSX conferences also provide a forum for direct investment programs, mutual funds, and asset management companies. For more information visit: http://www.fsxone.com/ .
Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International (http://www.oi-pnt.com/ ).
http://finance.yahoo.com/news/Sunridge-International-to-prnews-647352178.html?x=0&.v=1
You bet it is, just "envision" the possibilities to come.
The exposure to firms with clients and capital "in hand" to invest for additional growth in the future for SNDZ, OI, is an exciting thought.
Broker Dealers
FSX has a nationwide network of independent broker/dealers. Our member firms have a combined sales force of thousands of licensed professionals whose clients are looking to invest in companies of all sizes and capabilities.
Huge amount of broker/dealer's available at the conference for presenters.
http://www.fsx1.com/fsx/BrokerDealers/BrokerDealersNetwork/tabid/56/Default.aspx
A lot of great resource companies are going to be available at the conference for SNDZ, OI, don't you think?
FSX Resource Companies
When you’re trying to manage your business and monitor the needs of your clients, you don’t always have the time or monetary resources to hire on-staff specialists for legal services, compliance issue, and others. That’s what makes FSX so valuable. Our resource companies are reliable, reputable and knowledgeable in the areas most important to your business. Let them know you found them through FSX.
Nice news released this morning. Should be quite a few investors interested at the conference considering the importance of OI's work.
SNDZ - Sunridge International to Present at FSX Conference in San Francisco, CA
On Monday April 12, 2010, 9:00 am EDT
FOUNTAIN HILLS, Ariz., April 12 /PRNewswire-FirstCall/ -- Sunridge International, (OTC Bulletin Board:SNDZ.ob - News) will be presenting at the upcoming FSX (Financial Services Exchange, Inc.) investors conference being held in San Francisco, CA on April 29-May 1, 2010.
Sunridge International's CEO, G. Richard Smith, said, "Our marketing outreach program over the past two months has been a great success in gaining awareness throughout the U.S. investment community. This upcoming FSX Conference will allow us to continue to further our efforts to communicate the progress that Sunridge has made in recent months and the inroads it has made in several of the world's major markets."
About FSX
FSX hosts quarterly investment conferences around the country, providing opportunities for networking and one-on-one communication between independent broker/dealers and companies seeking exposure or funding. FSX is the oldest, most established U.S. forum for independent broker/dealers, and has raised over $1.5 billion for its presenters in the past 24 years. FSX conferences also provide a forum for direct investment programs, mutual funds, and asset management companies. For more information visit: http://www.fsxone.com/ .
Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International (http://www.oi-pnt.com/ ).
http://finance.yahoo.com/news/Sunridge-International-to-prnews-647352178.html?x=0&.v=1
SNDZ - Sunridge International to Present at FSX Conference in San Francisco, CA
On Monday April 12, 2010, 9:00 am EDT
FOUNTAIN HILLS, Ariz., April 12 /PRNewswire-FirstCall/ -- Sunridge International, (OTC Bulletin Board:SNDZ.ob - News) will be presenting at the upcoming FSX (Financial Services Exchange, Inc.) investors conference being held in San Francisco, CA on April 29-May 1, 2010.
Sunridge International's CEO, G. Richard Smith, said, "Our marketing outreach program over the past two months has been a great success in gaining awareness throughout the U.S. investment community. This upcoming FSX Conference will allow us to continue to further our efforts to communicate the progress that Sunridge has made in recent months and the inroads it has made in several of the world's major markets."
About FSX
FSX hosts quarterly investment conferences around the country, providing opportunities for networking and one-on-one communication between independent broker/dealers and companies seeking exposure or funding. FSX is the oldest, most established U.S. forum for independent broker/dealers, and has raised over $1.5 billion for its presenters in the past 24 years. FSX conferences also provide a forum for direct investment programs, mutual funds, and asset management companies. For more information visit: http://www.fsxone.com/ .
Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International (http://www.oi-pnt.com/ ).
http://finance.yahoo.com/news/Sunridge-International-to-prnews-647352178.html?x=0&.v=1
Highlights of the First World Glaucoma Congress: Glaucoma Worldwide
In the Opening Session, Professor Gullapallin Rao, from the L V Prasad Eye Institute, Hyderabad, who is President of the International Agency for the Prevention of Blindness (IAPB), outlined the origins of the IAPB in 1975. Recognizing the serious public health problem posed by global visual disability and blindness, a number of nongovernment organizations came together to collaborate with the World Health Organization. Their major thrust currently is the Vision2020 project, which aims to eliminate all avoidable blindness by that deadline -- and indeed, the numbers of blind persons are already down from original forecasts. The older blinding diseases were cataract, trachoma, and onchocerciasis, while the newer threats include cataract, glaucoma, and, increasingly, diabetic retinopathy. Glaucoma is second only to cataract in causing blindness.
Professor Rao outlined a pyramidal care structure that is being developed in the developing world in order to further the goals of Vision2020. He stated that there should be a primary eye care center per 50,000 individuals, secondary eye care center per 500,000, tertiary per 5 million, and advanced tertiary per 50 million people. It is the advanced tertiary eye care centers that train the trainers who filter down through the structure to provide the necessary services and to teach other health and eye care workers.
Professor Harry Quigley, of Johns Hopkins University, Baltimore, Maryland, detailed the extent of glaucoma as a worldwide health problem, noting that it accounts for 10 of the estimated 83 million bilaterally blind people -- but that figure is dependent on where you come from. Blindness is 10 times higher in the developing than in the developed world, and the risk of dying is 4 times higher in blind Africans than in other blind individuals. Updating his previously published figures, Professor Quigley estimated that of the 65 million people affected by glaucoma (44 million with open-angle, 21 million with angle-closure), 10 million are bilaterally blind. Whereas about 10% of the open-angle glaucoma patients are bilaterally blind, the figure for angle-closure is about 25%. Hence, more people are blind from angle closure, even though it is far less common.
Asia accounts for a disproportionate amount of the glaucoma burden: 60% overall and 80% of angle-closure. The reasons for this disparity are unclear, although angle closure can be partly explained by anatomic features: shallow anterior chamber, narrow angle, smaller eye (hence more females than males) and older age (larger crystalline lens increasing anterior segment crowding). But these factors do not explain why Chinese individuals have a 5 times greater risk compared with white individuals. Angle closure is historically difficult to diagnose. Worldwide, 85% of glaucoma is undiagnosed, but when it is diagnosed, it is primarily open-angle -- of every 5 patients being treated, 2 have open-angle glaucoma and 3 have ocular hypertension. Professor Quigley argued that physiologic factors must be involved in angle closure, and that physiologic testing should therefore be explored as a means for diagnosing angle closure.
Expanding on the discussion of public health issues posed by glaucoma, Professor Ivan Goldberg, from the University of Sydney, Australia, demonstrated that with the increase in population superimposed on the exponential increases in both population aging and glaucoma prevalence with increasing age, the challenges in detecting and managing both main types of glaucoma are rising dramatically. Educational strategies using guidelines, such as those published over the past few years by the American Academy of Ophthalmology, European Glaucoma Society, and the South East Asia Glaucoma Interest Group, are ever more relevant and important.
Did you take a read on the projected revenues for the 2010-2014 period?
Certainly makes ya "envision" the potential for SNDZ, OI, doesn't it?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=48818754
Glaucoma Worldwide: A Growing Concern
By Robert N. Weinreb, MD
The worldwide prevalence of glaucoma is increasing. This is due in part to the rapidly aging population. Vision loss from glaucoma greatly impacts the independence of many people who are part of this aging population.
In addition to the impact glaucoma has on personal lives, there is an increasing economic burden on society. As a visitor to the Glaucoma Research Foundation website, it is likely you may either have glaucoma or know someone close to you who is affected by it. Indeed, glaucoma can have a serious impact on your quality of life. In 2008, it is critical to reinforce the importance of preventing vision loss through timely diagnosis and appropriate treatment.
How common is glaucoma? At the current time there are more than 60 million people worldwide with glaucoma. Most interesting, about half of the people who have glaucoma don’t even know it. Think about that. In the United States, we have 4 million Americans who have glaucoma, and about half do not even know it.
The longer you live, the more likely you are to have glaucoma. In 2010, it is estimated we are going to have 8.4 million individuals worldwide who are blind from primary glaucoma. By the year 2020, it is estimated that there will be 11 million individuals who are blind from glaucoma.
Certain ethnic populations are at high risk. For some time we have known that individuals of African ancestry are at very high risk. We are now learning that Hispanic individuals and certain Asian populations also are at very high risk. In terms of treatment, there is a challenge to diagnose and treat glaucoma before vision loss has occurred.
Why is diagnosis and treatment delayed? One reason is that glaucoma is painless. Secondly, the visual symptoms are often very late. Only half of those who are actually diagnosed with glaucoma have any symptoms at all. Most of the time, a glaucoma patient is unaware of any vision loss. And elderly individuals, who are at the greatest risk for developing glaucoma, often attribute their loss of vision to just growing old. Vision loss from glaucoma is silent, it is slow, it is progressive, it is irreversible, but it is treatable. Glaucoma blindness is preventable.
How do we treat glaucoma? Currently, we reduce eye pressure to slow the worsening optic nerve damage, to preserve visual function and, most significantly, to preserve quality of life.
The key to preserving vision is timely diagnosis and treatment, through regular complete eye examinations; and the purpose of glaucoma treatment is to allow the glaucoma patient to maintain his or her independence and quality of life.
—
Robert N. Weinreb, MD is Distinguished Professor of Ophthalmology and Director of the Hamilton Glaucoma Center at the University of California, San Diego in La Jolla, CA. He is President of the American Glaucoma Society and serves on GRF’s Scientific Advisory Committee.
No I'm old school, just as soon hack away at it and cut, ya know what I mean? chuckle .
Snicker, "COKE"!
Took a look at the video for a simple, basic in office procedure for OI's PNT method. Interesting.
Link to PNT Video
International Distributors list for OI provides nice coverage, doesn't it?
http://www.oi-pnt.com/PNT_distributors.html
OH YES! certainly forgot that one! chuckle
Most certainly does. And with the largest segments of populations all over the world being "more advanced" in age, the need for more readily available healthcare and equipment at an affordable cost is increasing in importance, (cheaper, better, faster, easier, etc.), don't you think?
Sunridge International Makes Further Inroads Into Chinese Market
Receives Additional Orders for its Patented PNT Non-invasive Glaucoma Treatment
On Wednesday March 17, 2010, 9:00 am EDT
FOUNTAIN HILLS, Ariz., March 17 /PRNewswire-FirstCall/ -- Sunridge International (OTC Bulletin Board:SNDZ.ob - News), announced today it had received further orders for its patented Pneumatic Trabeculoplasty (PNT) non-invasive glaucoma treatment in China and said it's exclusive distributor, Beijing Vision World Trading Co. (BV) was moving forward rapidly with a robust nationwide marketing program.
Upon receiving China's State Food and Drug Administration approval last month to market (PNT) equipment and treatment, the company has embarked on an aggressive round of marketing that will embrace several hospitals, health authorities and ophthalmic specialists. Just weeks after placing their initial order for 30 vacuum units and 10,000 rings used in the treatment, Beijing Vision World said that they are placing further orders for an additional 30 units.
Sunridge International's CEO, G. Richard Smith, said that he was delighted with the progress the company was making in China. "We are fortunate to be handled by Beijing Vision World, an aggressive company, in one of the world's largest markets and we are especially pleased to think that our treatment, which has been perfected over a number of years, will soon be put to good use in helping, perhaps, many thousands of glaucoma sufferers in China," he said.
PNT is a safe, efficient and cost effective 2-minute non-invasive alternative treatment for glaucoma and ocular hypertension, that has been developed, patented, and distributed by Sunridge International's wholly owned subsidiary, Ophthalmic International. Further details of the company and its products can be found on the company's website (http://www.oi-pnt.com/ ).
http://finance.yahoo.com/news/Sunridge-International-Makes-prnews-3225826882.html?x=0&.v=1
Have to agree, especially the way it's been trading within this range for the last month.
The potential for a return to those higher levels should easily be obtainable for an International medical equipment manufacturer like OI.
With that amount of money flow and accumulation we're just waiting for something to "set it off", aren't we?
SNDZ info - Sunridge International Makes Further Inroads Into Chinese Market
Receives Additional Orders for its Patented PNT Non-invasive Glaucoma Treatment
On Wednesday March 17, 2010, 9:00 am EDT
FOUNTAIN HILLS, Ariz., March 17 /PRNewswire-FirstCall/ -- Sunridge International (OTC Bulletin Board:SNDZ.ob - News), announced today it had received further orders for its patented Pneumatic Trabeculoplasty (PNT) non-invasive glaucoma treatment in China and said it's exclusive distributor, Beijing Vision World Trading Co. (BV) was moving forward rapidly with a robust nationwide marketing program.
Upon receiving China's State Food and Drug Administration approval last month to market (PNT) equipment and treatment, the company has embarked on an aggressive round of marketing that will embrace several hospitals, health authorities and ophthalmic specialists. Just weeks after placing their initial order for 30 vacuum units and 10,000 rings used in the treatment, Beijing Vision World said that they are placing further orders for an additional 30 units.
Sunridge International's CEO, G. Richard Smith, said that he was delighted with the progress the company was making in China. "We are fortunate to be handled by Beijing Vision World, an aggressive company, in one of the world's largest markets and we are especially pleased to think that our treatment, which has been perfected over a number of years, will soon be put to good use in helping, perhaps, many thousands of glaucoma sufferers in China," he said.
PNT is a safe, efficient and cost effective 2-minute non-invasive alternative treatment for glaucoma and ocular hypertension, that has been developed, patented, and distributed by Sunridge International's wholly owned subsidiary, Ophthalmic International. Further details of the company and its products can be found on the company's website (http://www.oi-pnt.com/ ).
http://finance.yahoo.com/news/Sunridge-International-Makes-prnews-3225826882.html?x=0&.v=1
SNDZ info - Sunridge International Makes Further Inroads Into Chinese Market
Receives Additional Orders for its Patented PNT Non-invasive Glaucoma Treatment
On Wednesday March 17, 2010, 9:00 am EDT
FOUNTAIN HILLS, Ariz., March 17 /PRNewswire-FirstCall/ -- Sunridge International (OTC Bulletin Board:SNDZ.ob - News), announced today it had received further orders for its patented Pneumatic Trabeculoplasty (PNT) non-invasive glaucoma treatment in China and said it's exclusive distributor, Beijing Vision World Trading Co. (BV) was moving forward rapidly with a robust nationwide marketing program.
Upon receiving China's State Food and Drug Administration approval last month to market (PNT) equipment and treatment, the company has embarked on an aggressive round of marketing that will embrace several hospitals, health authorities and ophthalmic specialists. Just weeks after placing their initial order for 30 vacuum units and 10,000 rings used in the treatment, Beijing Vision World said that they are placing further orders for an additional 30 units.
Sunridge International's CEO, G. Richard Smith, said that he was delighted with the progress the company was making in China. "We are fortunate to be handled by Beijing Vision World, an aggressive company, in one of the world's largest markets and we are especially pleased to think that our treatment, which has been perfected over a number of years, will soon be put to good use in helping, perhaps, many thousands of glaucoma sufferers in China," he said.
PNT is a safe, efficient and cost effective 2-minute non-invasive alternative treatment for glaucoma and ocular hypertension, that has been developed, patented, and distributed by Sunridge International's wholly owned subsidiary, Ophthalmic International. Further details of the company and its products can be found on the company's website (http://www.oi-pnt.com/ ).
http://finance.yahoo.com/news/Sunridge-International-Makes-prnews-3225826882.html?x=0&.v=1
Since SNDZ(OI) has already received product approval for marketing from China's State Food and Drug Administration, have you heard anymore concerning China orders and their national marketing program?
Oh yeah, Just needing that catalyst to start the fire aren't we?
SNDZ +8.57% - Sunridge International's wholly owned subsidiary, Ophthalmic International has quite a bit going for them.
Approved for use in Canada and the European Economic Community (EEC)
Welcome to the global home page of Ophthalmic
International, which is leading the way in the development
of PNeumatic Trabeculoplasty (PNT). PNT is a safe,
noninvasive method clinically demonstrated to lower
elevated Intraocular Pressure (IOP) in patients with
Primary Open Angle Glaucoma (POAG), Pigmentary
Glaucoma or Ocular Hypertension.
Ophthalmic International, a private company, is
headquartered near Phoenix, Arizona and has a
European office outside of Rome, Italy. The company's
focus is on the development and commercialization of
Pneumatic Trabeculoplasty (PNT).
SNDZ +8.57% - Sunridge International's wholly owned subsidiary, Ophthalmic International has quite a bit going for them.
Approved for use in Canada and the European Economic Community (EEC)
Welcome to the global home page of Ophthalmic
International, which is leading the way in the development
of PNeumatic Trabeculoplasty (PNT). PNT is a safe,
noninvasive method clinically demonstrated to lower
elevated Intraocular Pressure (IOP) in patients with
Primary Open Angle Glaucoma (POAG), Pigmentary
Glaucoma or Ocular Hypertension.
Ophthalmic International, a private company, is
headquartered near Phoenix, Arizona and has a
European office outside of Rome, Italy. The company's
focus is on the development and commercialization of
Pneumatic Trabeculoplasty (PNT).
And just a reply on implied, "Point of Reference gig", for the AWYI board on some postings within this past week.
Any and all "newbies" recently this week making reference to anything related negatively to moderators, ("mods"), not being here. Foolishness, check the postings. Wasn't any reason for all to be here posting daily, but all still checking in and monitoring.
Ya'll have heard from, or have seen, EVERY MODERATOR on this board post this week! Both present and past! Hopefully gained some historical insight or information.
Additionally, (check the dates), all present and past moderators are open, and have always been open, to have given the IBox the same attention and time, as need be, that all shareholders have been given!
C'mon now, see the true value of loyal longs!? $$
As always hoping for the best here, and as always just in my opinion.
Sunridge International's wholly owned subsidiary, Ophthalmic International is quite impressive.
Approved for use in Canada and the European Economic Community (EEC)
Welcome to the global home page of Ophthalmic
International, which is leading the way in the development
of PNeumatic Trabeculoplasty (PNT). PNT is a safe,
noninvasive method clinically demonstrated to lower
elevated Intraocular Pressure (IOP) in patients with
Primary Open Angle Glaucoma (POAG), Pigmentary
Glaucoma or Ocular Hypertension.
Ophthalmic International, a private company, is
headquartered near Phoenix, Arizona and has a
European office outside of Rome, Italy. The company's
focus is on the development and commercialization of
Pneumatic Trabeculoplasty (PNT).
Excellent post for all here 'McKinley', thanks for sharing that.
http://www.emedicinehealth.com/primary_open-angle_glaucoma/article_em.htm
As stated, obviousily see that, LOL. And Ditto...
Hall Monitor...?
Grinning, can usually count on ya for the humorous retort, certainly enjoy it. Chuckle
And Ditto on the post.